Literature DB >> 23741009

Toward eliminating HLA class I expression to generate universal cells from allogeneic donors.

Hiroki Torikai1, Andreas Reik, Frank Soldner, Edus H Warren, Carrie Yuen, Yuanyue Zhou, Denise L Crossland, Helen Huls, Nicholas Littman, Ziying Zhang, Scott S Tykodi, Partow Kebriaei, Dean A Lee, Jeffrey C Miller, Edward J Rebar, Michael C Holmes, Rudolf Jaenisch, Richard E Champlin, Philip D Gregory, Laurence J N Cooper.   

Abstract

Long-term engraftment of allogeneic cells necessitates eluding immune-mediated rejection, which is currently achieved by matching for human leukocyte antigen (HLA) expression, immunosuppression, and/or delivery of donor-derived cells to sanctuary sites. Genetic engineering provides an alternative approach to avoid clearance of cells that are recognized as "non-self" by the recipient. To this end, we developed designer zinc finger nucleases and employed a "hit-and-run" approach to genetic editing for selective elimination of HLA expression. Electro-transfer of mRNA species coding for these engineered nucleases completely disrupted expression of HLA-A on human T cells, including CD19-specific T cells. The HLA-A(neg) T-cell pools can be enriched and evade lysis by HLA-restricted cytotoxic T-cell clones. Recognition by natural killer cells of cells that had lost HLA expression was circumvented by enforced expression of nonclassical HLA molecules. Furthermore, we demonstrate that zinc finger nucleases can eliminate HLA-A expression from embryonic stem cells, which broadens the applicability of this strategy beyond infusing HLA-disparate immune cells. These findings establish that clinically appealing cell types derived from donors with disparate HLA expression can be genetically edited to evade an immune response and provide a foundation whereby cells from a single donor can be administered to multiple recipients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23741009      PMCID: PMC3750336          DOI: 10.1182/blood-2013-03-478255

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

1.  Transient cold shock enhances zinc-finger nuclease-mediated gene disruption.

Authors:  Yannick Doyon; Vivian M Choi; Danny F Xia; Thuy D Vo; Philip D Gregory; Michael C Holmes
Journal:  Nat Methods       Date:  2010-05-02       Impact factor: 28.547

Review 2.  MHC class I molecules and KIRs in human history, health and survival.

Authors:  Peter Parham
Journal:  Nat Rev Immunol       Date:  2005-03       Impact factor: 53.106

3.  Derivation of pre-X inactivation human embryonic stem cells under physiological oxygen concentrations.

Authors:  Christopher J Lengner; Alexander A Gimelbrant; Jennifer A Erwin; Albert Wu Cheng; Matthew G Guenther; G Grant Welstead; Raaji Alagappan; Garrett M Frampton; Ping Xu; Julien Muffat; Sandro Santagata; Doug Powers; C Brent Barrett; Richard A Young; Jeannie T Lee; Rudolf Jaenisch; Maisam Mitalipova
Journal:  Cell       Date:  2010-05-13       Impact factor: 41.582

Review 4.  HLA compatibility and organ transplant survival. Collaborative Transplant Study.

Authors:  G Opelz; T Wujciak; B Döhler; S Scherer; J Mytilineos
Journal:  Rev Immunogenet       Date:  1999

5.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

Authors:  Renier J Brentjens; Isabelle Rivière; Jae H Park; Marco L Davila; Xiuyan Wang; Jolanta Stefanski; Clare Taylor; Raymond Yeh; Shirley Bartido; Oriana Borquez-Ojeda; Malgorzata Olszewska; Yvette Bernal; Hollie Pegram; Mark Przybylowski; Daniel Hollyman; Yelena Usachenko; Domenick Pirraglia; James Hosey; Elmer Santos; Elizabeth Halton; Peter Maslak; David Scheinberg; Joseph Jurcic; Mark Heaney; Glenn Heller; Mark Frattini; Michel Sadelain
Journal:  Blood       Date:  2011-08-17       Impact factor: 22.113

6.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Authors:  James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; Steven A Rosenberg
Journal:  Blood       Date:  2010-07-28       Impact factor: 22.113

7.  C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients.

Authors:  Scott S Tykodi; Nobuharu Fujii; Nathalie Vigneron; Sharon M Lu; Jeffrey K Mito; Maureen X Miranda; Jeffrey Chou; Lilien N Voong; John A Thompson; Brenda M Sandmaier; Peter Cresswell; Benoît Van den Eynde; Stanley R Riddell; Edus H Warren
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

8.  Class-, gene-, and group-specific HLA silencing by lentiviral shRNA delivery.

Authors:  Constança Figueiredo; Axel Seltsam; Rainer Blasczyk
Journal:  J Mol Med (Berl)       Date:  2006-03-07       Impact factor: 4.599

9.  Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy.

Authors:  Colleen M O'Connor; Sabina Sheppard; Cassie A Hartline; Helen Huls; Mark Johnson; Shana L Palla; Sourindra Maiti; Wencai Ma; R Eric Davis; Suzanne Craig; Dean A Lee; Richard Champlin; Heather Wilson; Laurence J N Cooper
Journal:  Sci Rep       Date:  2012-02-13       Impact factor: 4.379

10.  Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis.

Authors:  F Borrego; M Ulbrecht; E H Weiss; J E Coligan; A G Brooks
Journal:  J Exp Med       Date:  1998-03-02       Impact factor: 14.307

View more
  117 in total

Review 1.  New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target Malignancies.

Authors:  Thomas M Schmitt; Ingunn M Stromnes; Aude G Chapuis; Philip D Greenberg
Journal:  Clin Cancer Res       Date:  2015-10-13       Impact factor: 12.531

Review 2.  Smart CARs engineered for cancer immunotherapy.

Authors:  Saul J Priceman; Stephen J Forman; Christine E Brown
Journal:  Curr Opin Oncol       Date:  2015-11       Impact factor: 3.645

Review 3.  The present and future of genome editing in cancer research.

Authors:  Xiaoyi Li; Raymond Wu; Andrea Ventura
Journal:  Hum Genet       Date:  2016-07-18       Impact factor: 4.132

Review 4.  T-Cell Receptor-Based Immunotherapy for Hematologic Malignancies.

Authors:  Melinda A Biernacki; Michelle Brault; Marie Bleakley
Journal:  Cancer J       Date:  2019 May/Jun       Impact factor: 3.360

Review 5.  Versatile CAR T-cells for cancer immunotherapy.

Authors:  Fuliang Chu; Jingjing Cao; Sattva S Neelalpu
Journal:  Contemp Oncol (Pozn)       Date:  2018-03-05

Review 6.  Methods to manufacture regulatory T cells for cell therapy.

Authors:  K N MacDonald; J M Piret; M K Levings
Journal:  Clin Exp Immunol       Date:  2019-04-15       Impact factor: 4.330

Review 7.  A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19.

Authors:  Harjeet Singh; Helen Huls; Partow Kebriaei; Laurence J N Cooper
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 8.  Cell Therapy for Type 1 Diabetes: Current and Future Strategies.

Authors:  Yasaman Aghazadeh; Maria Cristina Nostro
Journal:  Curr Diab Rep       Date:  2017-06       Impact factor: 4.810

Review 9.  Paving the way towards universal treatment with allogenic T cells.

Authors:  Michelle H Townsend; Kelsey Bennion; Richard A Robison; Kim L O'Neill
Journal:  Immunol Res       Date:  2020-02       Impact factor: 2.829

Review 10.  Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.

Authors:  William R Strohl; Michael Naso
Journal:  Antibodies (Basel)       Date:  2019-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.